“Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon” (2017) Revista de Medicina de la Universidad de Navarra, 40(3), pp. 6–12. doi:10.15581/021.8892.